Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
Sign Up to like & getrecommendations! Published in 2017 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/sigtrans.2016.45
Abstract: Fibroblast growth factor 2 (FGF-2) is overexpressed in a subset of invasive bladder carcinomas and its overexpression correlates with poor prognosis. Analyses of publicly available databases addressing the molecular mechanisms that may be responsible for… read more here.
Keywords: publicly available; analyses publicly; bladder carcinomas; bladder ... See more keywords
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29030117
Abstract: Background: Urothelial bladder carcinomas had traditionally been difficult to treat cancers, with high morbidity and mortality rates when invasive and metastatic. In recent years, immunotherapy with immune checkpoint inhibitors has improved outcomes in several cancers,… read more here.
Keywords: carcinomas; high tmb; carcinomas high; tmb ... See more keywords